Miromatrix is a leading regenerative medicine/ life science company bioengineering transplantable organs to eliminate the organ transplant waiting list, including livers, kidneys, lungs and hearts based on its patented perfusion decellularization and recellularization technologies. The company’s approach has the potential to end the transplantable organ shortage and access billion-dollar market opportunities and was recently recognized with a KidneyX prize. We recently completed our FDA INTERACT meeting, published our initial liver work in Nature Biomedical Engineering, were awarded a direct to Phase II SBIR grant and proud to have been named the 2019 Buzz of BIO for the Pipeline of Promise.
The company is seeking a $2SM Series C round of capital to advance ongoing research and development activities, including funding the initiation of the Phase I clinical trial and first human implant of the bioengineered liver, and completion of the IND enabling study for a bioengineered kidney with the FDA.
Miromatrix’ lead program is a bioengineered liver to treat end stage liver disease (ESLD), and Phase I clinical studies are targeted as early as 2022. The second advanced program is a bioengineered kidney to treat end stage renal disease (ESRD), and Phase I clinical studies are targeted for 2023. Significant progress towards the goal, including the ability to revascularize the liver and kidney grafts, transplant them back into large animals, obtain sustained perfusion and demonstrate function. In addition, Miromatrix has successfully commercialized the decellularized matrix including completing two prospective clinical trials and implantations into thousands of patients to provide human data.
Radio Broadcast Feature
Begin listening at :34 in the podcast.
Get access to the important information you need from Farmers for Innovation. Using the fields below, please provide your information so that we may reach out regarding next steps and access to the FFI Data Room.